Enovis (ENOV) Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENOV shares.
View ENOV analyst ratings or view top-rated stocks.

6 analysts have issued twelve-month price targets for Enovis' stock. Their ENOV share price forecasts range from $57.00 to $70.00. On average, they anticipate the company's share price to reach $65.29 in the next year. This suggests a possible upside of 24.1% from the stock's current price.
View analysts price targets for ENOV or view top-rated stocks among Wall Street analysts.

Enovis' stock was trading at $53.52 at the beginning of the year. Since then, ENOV stock has decreased by 1.7% and is now trading at $52.59.
View the best growth stocks for 2023 here.

Enovis saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,690,000 shares, an increase of 10.2% from the August 15th total of 2,440,000 shares. Based on an average trading volume of 357,800 shares, the short-interest ratio is presently 7.5 days. Approximately 5.4% of the shares of the stock are short sold.
View Enovis' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ENOV earnings forecast.

Enovis Co. (NYSE:ENOV) issued its earnings results on Thursday, August, 3rd. The company reported $0.61 earnings per share for the quarter, beating analysts' consensus estimates of $0.53 by $0.08. The business earned $428.50 million during the quarter, compared to the consensus estimate of $420.06 million. Enovis had a positive trailing twelve-month return on equity of 3.74% and a negative net margin of 8.52%. The company's revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.59 EPS.

ETFs with the largest weight of Enovis (NYSE:ENOV) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P MidCap 400 Pure Value ETF (RFV) and Dimensional US Small Cap Value ETF (DFSV).iShares U.S. Medical Devices ETF (IHI).

Enovis issued an update on its FY 2023 earnings guidance on Friday, September, 22nd. The company provided earnings per share (EPS) guidance of $2.22-$2.36 for the period, compared to the consensus estimate of $2.31. The company issued revenue guidance of -.

Enovis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENOV."

Enovis' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.10%), Dimensional Fund Advisors LP (5.44%), Diamond Hill Capital Management Inc. (4.05%), Thrivent Financial for Lutherans (3.25%), State Street Corp (2.81%) and Durable Capital Partners LP (2.79%). Insiders that own company stock include A Clayton Perfall, Bradley J Tandy, Brady Shirley, Christopher M Hix, Daniel A Pryor, John Kleckner, Matthew L Trerotola, Patricia A Lang, Phillip Benjamin (Ben) Berry and Rajiv Vinnakota.
View institutional ownership trends.

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENOV stock can currently be purchased for approximately $52.59.

Enovis (NYSE:ENOV) has a market capitalization of $2.87 billion and generates $1.56 billion in revenue each year. The company earns $-13,290,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

The company employs 6,800 workers across the globe.

Enovis' mailing address is 2711 Centerville Road Suite 400, Wilmington DE, 19808. The official website for the company is www.enovis.com. The company can be reached via phone at 302-252-9160, via email at investorrelations@colfaxcorp.com, or via fax at 301-323-9001.